lorus6k.htm

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the Month of December, 2012

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant’s name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_______________.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Lorus Therapeutics Inc.


Date: December 5, 2012	By:	/s/ “Elizabeth Williams”
		Elizabeth Williams
		Director of Finance and Controller

99.1	News Release Dated December 4, 2012 - Lorus Therapeutics Announces Positive Anticancer Data for IL-17E at AACR Tumor Immunology Conference

99.2	Report of Voting Results

Lorus Therapeutics Announces Positive Anticancer Data for

IL-17E at AACR Tumor Immunology Conference

TORONTO, CANADA, December 4, 2012 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus”), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced the presentation of new data to support the development of its novel oncology product IL-17E at the 2012 American Association for Cancer Research (AACR) Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances Conference.

The presentation provides an overview of recent preclinical studies conducted by Lorus to assess the anticancer activity and safety of IL-17E. The studies show that IL-17E significantly inhibits the growth of colon and melanoma cancers in animal models, with no apparent signs of toxicity. The animal models used provide both a more complete assessment of the safety of IL-17E, and confirmation of the efficacy of IL-17E at safe doses. This is essential information for Lorus’ strategy to bring IL-17E into clinical studies to treat human cancers.

IL-17E is a novel cytokine-based cancer therapy that stimulates the immune system to inhibit tumor cell growth. IL-17E also directly attacks and kills cancer cells that have the IL-17E receptor, while having minimal activity on normal cells. The data presented today show for the first time that IL-17E is active against colon and melanoma tumors that have the IL-17E receptor, and support development of IL-17E as a potential new and safe approach for treating these kinds of cancers.

The direct tumor targeting property of IL-17E also provides a scientific rationale for selecting patients with the appropriate cancers that possess the IL-17E receptor and therefore more likely to benefit from IL-17E treatment.

“We are very pleased to have the opportunity to present our data at this special AACR conference focused on cutting-edge developments in tumor immunology and cancer immunotherapies.” said Dr. Aiping Young, Lorus' President and CEO. “Having recently entered into an agreement with a partner who will fund and develop the program through a Phase I clinical trial, the extension of the evidence to colon cancer and melanoma is important for drug development and commercialization strategies.”

The 2012 AACR Tumor Immunology Conference highlights developing technological advances aimed at understanding the inflammatory responses that contribute to cancer development and progression, and new methods of targeting the immune system for cancer prevention and treatment. The conference is being held in Miami, Florida, from December 2-5, 2012.

About IL-17E

IL-17E is a novel biological therapy based on human interleukin 17E, which is a cytokine protein that acts on cells of the immune system. IL-17E, which is in preclinical development, has potent anticancer properties against a range of solid tumors, including pancreatic, colon, lung, ovarian and breast cancers. IL-17E showed equivalent or superior efficacy as a single agent compared to marketed drugs used to treat these cancers, including Avastin, Tarceva, Taxotere, Taxol, Cisplatin, and Gemzar. IL-17E was also effective when used in combination with these drugs, and demonstrated antitumor efficacy that was greater than either agent alone without additional toxicity.

About Lorus

Lorus is a biopharmaceutical company focused on the discovery, research and development of novel therapeutics in cancer. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. The Company also has expertise in antimicrobial drug discovery. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to continue as a going concern, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “believe”, “plan”, “expect”, “intend”, “will”, “should”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to continue as a going concern, our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.’s recent press releases are available through the Company’s website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to www.Sedar.com.

Enquiries:

For further information, please contact:

Grace Tse, 416-798-1200 ext. 380; ir@lorusthera.com

Report of Voting Results

Lorus Therapeutics Inc.

In accordance with Section 11.3 of National Instrument 51-102, the following describes the matters voted upon and the outcome of the votes at the annual and special meeting of shareholders of Lorus Therapeutics Inc. (the “Corporation”) held on November 29, 2012 in Toronto, Ontario.

By a resolution passed by a majority of the votes cast by a show of hands, each of the following directors were elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed:

Herbert Abramson

Denis Burger

Mark Vincent

Warren Whitehead

Jim Wright

Aiping Young

The ballots cast were 99.45% in favour of the resolution with 0.00% against and 0.55% withheld.

By a resolution passed by a majority of the votes cast by a show of hands, KPMG LLP was re-appointed as auditors of the Corporation to hold office until the next annual meeting or until their successors are appointed, and the directors were authorized to fix their remuneration.

The ballots cast were 99.84% in favour of the resolution with 0.00% against and 0.16% withheld.

By ballot (of which approximately 99.39% of the votes represented at the meeting voted in favour and approximately 0.61% of the votes represented at the meeting voted against) the resolutions contained on page 14 of the Corporation’s Management Information Circular (a copy of which is attached hereto) were passed relating to the proposed amendments to the Corporation’s Deferred Share Unit Plan.

In total, 18,026,147 shares of the Corporation (representing approximately 42.66% of the issued and outstanding shares) were represented in person or by proxy at the meeting.

Yours very truly,

/s/ Elizabeth Williams

Elizabeth Williams

Director of Finance and Secretary

EXTRACT FROM PAGE 14 OF THE

CORPORATIONS’ MANAGEMENT INFORMATION CIRCULAR

CORPORATION’S DEFERRED SHARE UNIT PLAN

BE IT RESOLVED THAT:

The Corporation is hereby authorized to amend its deferred share unit plan (the “DSU Plan”) to (i) permit the issuance from treasury of common shares of the Corporation (the “Shares”) that are issuable under the DSU Plan; and (ii) set the maximum total number of Shares available for issuance from treasury under all security based compensation arrangement of the Corporation at 15% of the Corporation’s issued and outstanding Shares at any given time, the whole as set out in Appendix A to the management proxy circular of the Corporation dated October 15, 2012;

The Corporation is hereby authorized to issue shares from treasury in payment of any amount due under the DSU Plan, including for the deferred share units to acquire 780,000 Shares credited to Dr. Aiping Young, President and Chief Executive Officer of the Corporation, before the date hereof; and

Any director or officer of the Corporation is authorized and directed to execute and deliver for and in the name of and on behalf of the Corporation, under its corporate seal or otherwise, all such certificates, instruments, agreements, notices and other documents and to do such other acts and things as, in the opinion of such persons, may be necessary or desirable in connection with the amendments to the DSU Plan, with the performance of the Corporation of its obligations in connection therewith, and to give effect to the foregoing and facilitate the implementation of the foregoing resolutions.